Sensitivity of fecal immunochemical test and risk factors for interval colorectal cancer in a French population

Mikaël, Canévet; Manon, Pruvost-Couvreur; Morvan, Marie; Bogdan, Badic; Josiane, Brousse-Potocki; Kermarrec, Tiphaine; Servane, Bouzeloc; Jean-Baptiste, Nousbaum; Robaszkiewicz, Michel; Reboux, Noémi; Quénéhervé, Lucille

doi:10.1016/j.clinre.2023.102093

Cited by 4 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These differences are well established, with a strong association between gender, CRC incidence, and mortality. Some studies have reported decreased FIT sensitivity in women compared with men 28,29 . However, a large recent meta-analysis reported no significant difference in FIT sensitivity by gender 30 .…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Performance of OC-Auto Micro 80 Fecal Immunochemical Test in an Integrated Academic-Community Health System

Durowoju,

Mathias,

Bell-Brown

et al. 2023

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

Goals: We aimed to determine the performance of the OC-Auto Micro 80 fecal immunochemical test (FIT) in an average-risk population receiving care in an integrated, academic-community health system. Background: The FIT is the most used colorectal cancer (CRC) screening test worldwide. However, many Food and Drug Administration–cleared FIT products have not been evaluated in clinical settings. Study: We performed a retrospective cohort study of patients (50 to 75 y old) in the University of Washington Medicine health care system who were screened for CRC by OC-Auto Micro 80 FIT between March 2016 and September 2021. We used electronic health records to extract patient-level and clinic-level factors, FIT use, colonoscopy, and pathology findings. The primary outcomes were the FIT positivity rate and neoplasms detected at colonoscopy. Secondary outcomes were FIT positivity by sex and safety-net versus non–safety-net clinical settings. Results: We identified 39,984 FITs completed by 26,384 patients; 2411 (6.0%) had a positive FIT result (>100 ng/mL of hemoglobin in buffer), and 1246 (51.7%) completed a follow-up colonoscopy. The FIT positive rate was 7.0% in men and 5.2% in women (P <0.01). Among those who completed a colonoscopy after an abnormal FIT result, the positive predictive value for CRC, advanced adenoma, and advanced neoplasia was 3.0%, 20.9%, and 23.9%, respectively. Conclusions: In a retrospective analysis of a large heterogeneous population, the OC-Auto Micro 80 FIT for CRC screening demonstrated a positivity rate of 6.0% and a positive predictive value for CRC of 3.0%.

show abstract

Section: Discussionmentioning

confidence: 97%

“…Some studies have reported decreased FIT sensitivity in women compared with men. 28 , 29 However, a large recent meta-analysis reported no significant difference in FIT sensitivity by gender. 30 Altogether, these findings provide evidence to guide health systems when selecting a preferred FIT for CRC screening.…”

Section: Discussionmentioning

confidence: 99%

Performance of OC-Auto Micro 80 Fecal Immunochemical Test in an Integrated Academic-Community Health System

Durowoju,

Mathias,

Bell-Brown

et al. 2023

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

show abstract

“…For instance, its sensitivity for early-stage cancer is relatively low, standing at 40% 26. Additionally, a single study reported FIT’s sensitivity for proximal CRC is notably lower than for distal CRC, with a significant difference (71.1% vs 94.2%, p<0.001) 27. Furthermore, the participation rate in FIT screening hovers around 50% 28 29.…”

Section: Discussionmentioning

confidence: 99%

“… 26 Additionally, a single study reported FIT’s sensitivity for proximal CRC is notably lower than for distal CRC, with a significant difference (71.1% vs 94.2%, p<0.001). 27 Furthermore, the participation rate in FIT screening hovers around 50%. 28 29 In contrast, exhaled H 2 S analysis offers a breakthrough by addressing the limitations associated with bleeding and eliminating the influence of other haemorrhagic conditions on FIT results, such as haemorrhoids.…”

Section: Discussionmentioning

confidence: 99%

Role of exhaled hydrogen sulfide in the diagnosis of colorectal cancer

Du,

Tseng,

Liu

et al. 2024

BMJ Open Gastroenterol

View full text Add to dashboard Cite

BackgroundColorectal cancer (CRC) is often accompanied by increased excretion of hydrogen sulfide (H2S). This study aimed to explore the value of exhaled H2S in the diagnosis of CRC.MethodsA total of 80 people with normal colonoscopy results and 57 patients with CRC were enrolled into the present observational cohort study. Exhaled oral and nasal H2S were detected by Nanocoulomb breath analyser. Results were compared between the two groups. Receiver operating characteristic (ROC) curves were analysed and area under the curves (AUCs) were calculated to assess the diagnostic value of exhaled H2S. Meanwhile, the clinicopathological features, including gender, lesion location and tumour staging of patients with CRC, were also collected and analysed.ResultsThe amount of exhaled H2S from patients with CRC was significantly higher than that of those with normal colonoscopy results. The ROC curve showed an AUC value of 0.73 and 0.71 based on oral and nasal H2S detection, respectively. The exhaled H2S in patients with CRC was correlated with gender, lesion location and tumour progression, including depth of invasion, lymphatic metastasis and TNM (Tumor, Lymph Nodes, Metastasis) staging.ConclusionExhaled H2S analysis is a convenient and non-invasive detection method for diagnosing CRC, suggesting a potential role in population screening for CRC.

show abstract